Accelerating Neurodegenerative Clinical Drug Development with AI

Artificial Intelligence (AI) is revolutionizing the landscape of drug discovery and clinical drug development, particularly within Central Nervous System (CNS) research for neurodegenerative diseases. The emerging importance of AI in neurodegenerative diseases is underscored by the fact that CNS drug development, in general, has higher failure rates than non-CNS drugs, both preclinically and clinically, indicating that more research is required to ensure safety and efficacy in treatments to slow neurodegeneration.

Development times for neurodegenerative disease drugs are significantly longer, particularly for those that are ultimately approved. These approved therapies tend to be mainly symptomatic treatments or have only a minor to moderate effect on slowing disease progression. Additionally, the post-development regulatory review process is often extended. Failure rates are mainly due to the complexity of the brain and nervous system and lack of understanding of the underlining mechanisms that lead to brain disorders and neurodegeneration. As a result, neurodegenerative drug discovery and development programs have been subjected to significant cutbacks and eliminations over the last decades, affecting the entire drug development pipeline, from discovery through to clinical trials and regulatory approval.

Rapid advancements in AI are revolutionizing CNS clinical trials in neurodegenerative diseases by improving patient recruitment, optimizing study protocols, analyzing data in greater depth, and personalizing treatments. These advances not only enable more efficient and accurate clinical trials, but also speed up the development of new treatments and improve patient outcomes.

The integration of AI enhances understanding of mechanisms, accelerates novel target identification, and fuels advances in drug discovery for neurodegenerative diseases and other CNS disorders. It aids in generating compounds with unique properties, such as improved specificity or bioavailability. Overall, AI holds immense promise for understanding, diagnosing, and managing neurodegenerative diseases, ultimately improving patient outcomes.

In this webinar, you will learn:

• The role of AI in dissecting disease pathogenesis
• Ways AI can improve success rates in neurodegenerative drug discovery
• Methods for accelerating CNS clinical trials with AI, enhancing patient journeys and drug accessibility